These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

757 related items for PubMed ID: 15637398

  • 1. Prevention of hormone-related cancers: breast cancer.
    Dunn BK, Wickerham DL, Ford LG.
    J Clin Oncol; 2005 Jan 10; 23(2):357-67. PubMed ID: 15637398
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK, Ryan A.
    Ann N Y Acad Sci; 2009 Feb 10; 1155():141-61. PubMed ID: 19250201
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM.
    Clin Cancer Res; 2003 Jan 10; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK, Ford LG.
    Eur J Cancer Prev; 2007 Jun 10; 16(3):232-42. PubMed ID: 17415094
    [Abstract] [Full Text] [Related]

  • 8. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC.
    Eur J Cancer; 2006 Nov 10; 42(17):2909-13. PubMed ID: 17064889
    [Abstract] [Full Text] [Related]

  • 9. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ, Craig Jordan V.
    Minerva Endocrinol; 2002 Jun 10; 27(2):127-39. PubMed ID: 11961504
    [Abstract] [Full Text] [Related]

  • 10. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec 15; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 13. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT, Robert NJ.
    Eur J Cancer; 2005 Aug 15; 41(12):1678-89. PubMed ID: 16098456
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb 15; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL, Cheng MH, Chao HT, Wang PH.
    Taiwan J Obstet Gynecol; 2008 Mar 15; 47(1):24-31. PubMed ID: 18400579
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aromatase inhibitors and breast cancer.
    Miller WR.
    Minerva Endocrinol; 2006 Mar 15; 31(1):27-46. PubMed ID: 16498362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.